Vanguard Group
OCUL icon

Vanguard Group’s Ocular Therapeutix OCUL Stock Holding History

Vanguard Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$141M Buy
11,575,193
+2,411,953
+26% +$29.3M ﹤0.01% 1717
2025
Q3 		$107M Buy
9,163,240
+771,065
+9% +$9.22M ﹤0.01% 1830
2025
Q2 		$77.9M Buy
8,392,175
+27,660
+0.3% +$216K ﹤0.01% 1933
2025
Q1 		$61.3M Sell
8,364,515
-119,398
-1% -$918K ﹤0.01% 2008
2024
Q4 		$72.5M Buy
8,483,913
+99,730
+1% +$973K ﹤0.01% 2004
2024
Q3 		$72.9M Sell
8,384,183
-227,918
-3% -$1.88M ﹤0.01% 2025
2024
Q2 		$58.9M Buy
8,612,101
+1,376,970
+19% +$8.5M ﹤0.01% 2082
2024
Q1 		$65.8M Buy
7,235,131
+2,117,029
+41% +$15M ﹤0.01% 2052
2023
Q4 		$22.8M Buy
5,118,102
+1,057,123
+26% +$3.13M ﹤0.01% 2535
2023
Q3 		$12.8M Buy
4,060,979
+8,152
+0.2% +$33.4K ﹤0.01% 2741
2023
Q2 		$20.9M Buy
4,052,827
+11,437
+0.3% +$68K ﹤0.01% 2572
2023
Q1 		$21.3M Buy
4,041,390
+64,537
+2% +$306K ﹤0.01% 2561
2022
Q4 		$11.2M Buy
3,976,853
+25,047
+0.6% +$82.9K ﹤0.01% 2903
2022
Q3 		$16.4M Buy
3,951,806
+53,255
+1% +$268K ﹤0.01% 2717
2022
Q2 		$15.7M Sell
3,898,551
-296,855
-7% -$1.12M ﹤0.01% 2766
2022
Q1 		$20.8M Buy
4,195,406
+116,383
+3% +$645K ﹤0.01% 2752
2021
Q4 		$28.4M Buy
4,079,023
+394,174
+11% +$3.06M ﹤0.01% 2655
2021
Q3 		$36.8M Buy
3,684,849
+15,884
+0.4% +$178K ﹤0.01% 2527
2021
Q2 		$52M Buy
3,668,965
+25,902
+0.7% +$394K ﹤0.01% 2354
2021
Q1 		$59.8M Buy
3,643,063
+93,065
+3% +$1.79M ﹤0.01% 2218
2020
Q4 		$73.5M Buy
3,549,998
+571,235
+19% +$8.48M ﹤0.01% 1997
2020
Q3 		$22.7M Sell
2,978,763
-28,396
-0.9% -$236K ﹤0.01% 2397
2020
Q2 		$25.1M Buy
3,007,159
+907,320
+43% +$6.01M ﹤0.01% 2309
2020
Q1 		$10.4M Buy
2,099,839
+91,032
+5% +$449K ﹤0.01% 2605
2019
Q4 		$7.93M Sell
2,008,807
-2,189
-0.1% -$7.61K ﹤0.01% 2966
2019
Q3 		$6.11M Buy
2,010,996
+139,049
+7% +$622K ﹤0.01% 3060
2019
Q2 		$8.24M Buy
1,871,947
+234,360
+14% +$868K ﹤0.01% 2971
2019
Q1 		$6.5M Buy
1,637,587
+50,534
+3% +$203K ﹤0.01% 3037
2018
Q4 		$6.32M Buy
1,587,053
+159,520
+11% +$879K ﹤0.01% 2985
2018
Q3 		$9.82M Buy
1,427,533
+92,335
+7% +$579K ﹤0.01% 2930
2018
Q2 		$9.01M Sell
1,335,198
-9,343
-0.7% -$64.2K ﹤0.01% 2956
2018
Q1 		$8.75M Buy
1,344,541
+273,677
+26% +$1.54M ﹤0.01% 2882
2017
Q4 		$4.77M Buy
1,070,864
+41,960
+4% +$214K ﹤0.01% 3154
2017
Q3 		$6.36M Buy
1,028,904
+123,448
+14% +$795K ﹤0.01% 3017
2017
Q2 		$8.39M Buy
905,456
+3,194
+0.4% +$30.9K ﹤0.01% 2859
2017
Q1 		$8.37M Buy
902,262
+174,688
+24% +$1.45M ﹤0.01% 2840
2016
Q4 		$6.09M Sell
727,574
-22,300
-3% -$173K ﹤0.01% 2973
2016
Q3 		$5.15M Buy
749,874
+270,565
+56% +$1.65M ﹤0.01% 2989
2016
Q2 		$2.37M Buy
479,309
+23,793
+5% +$236K ﹤0.01% 3322
2016
Q1 		$4.4M Buy
455,516
+3,938
+0.9% +$29.8K ﹤0.01% 3032
2015
Q4 		$4.23M Buy
451,578
+22,163
+5% +$239K ﹤0.01% 3064
2015
Q3 		$6.04M Buy
429,415
+118,883
+38% +$2.39M ﹤0.01% 2881
2015
Q2 		$6.53M Buy
310,532
+137,530
+79% +$3.41M ﹤0.01% 2880
2015
Q1 		$7.26M Buy
173,002
+98,663
+133% +$3.24M ﹤0.01% 2804
2014
Q4 		$1.75M Buy
74,339
+35,017
+89% +$589K ﹤0.01% 3333
2014
Q3 		$588K Buy
+39,322
New +$581K ﹤0.01% 3674

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group's OCUL Position: Q4 2025 in Review

Vanguard Group increased its Ocular Therapeutix (OCUL) stake by 26% in Q4 2025, buying an estimated $29.3M and bringing the position to 11,575,193 shares worth $141M. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

Vanguard Group first reported a position in OCUL in Q3 2014 and has held it in 46 quarters since. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

  • Vanguard Group held 11,575,193 shares of Ocular Therapeutix worth $141M as of Q4 2025.
  • Vanguard Group bought 2,411,953 Ocular Therapeutix shares in Q4 2025, an estimated $29.3M.
  • Ocular Therapeutix made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1717 holding.
  • Vanguard Group first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 46 quarters since.
  • 249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.